science wire

« BACK

Pharmacology



Results 601 - 650 of 1620.
« Previous 1 ... 9 10 11 12 13 14 15 16 17 ... 33 Next »


Pharmacology - Health - 17.05.2018
Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analysed, including people with EGFR and ALK mutations, liver me

Pharmacology - Life Sciences - 16.05.2018
Cellular Valve Structure Opens Up Potential Novel Therapies
Cellular Valve Structure Opens Up Potential Novel Therapies
Human cells are enclosed by membranes and are in osmotic equilibrium with their environment. If the concentration of solute molecules (osmolarity) in the fluid surrounding the cells decreases, cells start to swell; in extreme cases, this can result in the cells bursting.

Business / Economics - Pharmacology - 16.05.2018

Pharmacology - Health - 14.05.2018
Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without factor VIII inhibitors Ongoing Hemli

Pharmacology - Health - 12.05.2018
Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)   In a landmark controlled

Pharmacology - Health - 10.05.2018
Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche today announc

Pharmacology - Health - 09.05.2018
Spinal fluid could be used to predict the progression of multiple sclerosis
Rheumatoid arthritis (RA) patients of South Asian origin now have extra help in living with a painful and incurable condition - thanks to a new educational video that encourages them to understand when and why they need to move from standard treatment to treatment with a biologic.

Pharmacology - Health - 07.05.2018
FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche today announced that the US Fo

Pharmacology - Health - 30.04.2018
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48 Pr

Health - Pharmacology - 30.04.2018
Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant melanoma
Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection  

Business / Economics - Pharmacology - 29.04.2018
New sources prove a Frenchman was one of the translators of the King James Bible
Significant political and economic uncertainty characterises the Brexit process one year after the UK triggered Article 50, reveals a new report by the academic group, The UK in a Changing Europe, which includes University of Birmingham Researchers.

Health - Pharmacology - 27.04.2018
CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin

Pharmacology - Health - 17.04.2018
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years   Commitment includes expanding access to pediatric antimalarials and imp

Pharmacology - Health - 17.04.2018
FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior fact

Pharmacology - Health - 17.04.2018
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures The LIBERTY trial studie

Health - Pharmacology - 16.04.2018
New educational video helps South Asian rheumatoid arthritis patients manage condition and understand treatment pathway
Scientists at the University of Birmingham have been awarded nearly £3 million from Cancer Research UK to investigate cancers that are resistant to treatment.

Health - Pharmacology - 16.04.2018
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes Heart failure (HF) patients with reduced

Pharmacology - Health - 10.04.2018
Plants ’hedge their bets’ in germination: the route to better crop yields
A study by the University of Birmingham has revealed a treatment gap in patients suffering from a heart condition that causes an irregular or abnormally fast heartbeat. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major global public health problem. It is associated with a five-fold increase in risk of stroke.

Health - Pharmacology - 07.04.2018
Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation
Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World Healt

Health - Pharmacology - 04.04.2018
Novartis announces JAMA Cardiology publication of data showing Entresto improves physical and social activity in HFrEF patients versus enalapril
Novartis announces JAMA Cardiology publication of data showing Entresto improves physical and social activity in HFrEF patients versus enalapril Post-hoc analysis of PARADIGM-HF published in JAMA Car

Health - Pharmacology - 04.04.2018
Enhanced therapeutic vaccine platform achieves two proof of concepts in veterinary medical use
Enhanced therapeutic vaccine platform achieves two proof of concepts in veterinary medical use
Chronical allergic diseases of dogs and horses can now be treated with an innovative vaccine. It was developed by an international research team led by he University of Bern and in cooperation with the University of Zurich, together with private enterprise companies. The findings obtained in horses and dogs could lead to similar herapeutic vaccines for humans.

Health - Pharmacology - 04.04.2018
Therapeutic vaccine platform achieves proof of concepts in veterinary medical use
Scientists from the Universities of Bern, Zurich and Oxford as well as the Latvian Biomedical Research & Study Centre led by Prof. Martin F. Bachmann (University Clinic of Rheumatology, Immunoloy and Allergology, University of Bern) have developed a new therapeutic vaccine technology based upon enhanced virus like nanoparticle conjugates.

Pharmacology - Health - 28.03.2018
Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co.

Pharmacology - Health - 28.03.2018
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, Honolulu, April 29 - May 3.

Pharmacology - Health - 26.03.2018
Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Phase III IMpower150 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin pl

Pharmacology - Health - 23.03.2018
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients   Results demonstrate siponimod al

Health - Pharmacology - 22.03.2018
Novartis drug Tasigna approved by FDA to treat children with rare form of leukemia
Tasigna (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy   New indication approved under FDA Prior

Health - Pharmacology - 22.03.2018
North and South Cooperation to Combat Tuberculosis
North and South Cooperation to Combat Tuberculosis
More than 4,000 people worldwide die from tuberculosis every day. This means the disease tops the list of the most common causes of death that result from a single pathogen.

Health - Pharmacology - 21.03.2018

Pharmacology - Health - 20.03.2018
Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Phase III IMpower131 study showed Roche's TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with

Health - Pharmacology - 19.03.2018
LSD Blurs Boundaries between the experience of Self and Other
Virtually all mental health disorders come with difficulties in interpersonal relations that in the long run negatively affect the progression of the disease. The associated health an social restrictions can only be marginally improved by current forms of therapy. One of the reasons for this is that there has been very little research into the basic neurobiological principles and in particular the neurochemical mechanisms of these kinds of disorders.

Health - Pharmacology - 07.03.2018
Global experts speak at first-ever International Congress on Clean Cooling
Scientists at the University of Birmingham are set to receive a major cash boost for pioneering research into cancer. Cancer Research UK is planning to invest nearly £11m over the next five years in ground-breaking work being carried out by the University of Birmingham-based Cancer Research UK Clinical Trials Unit (CRCTU)*.

Health - Pharmacology - 06.03.2018
Novartis’ Xolair recommended in new global chronic urticaria guideline
Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) , is the only therapy recommended by the guideline for patients unresponsive to antihistamine
« Previous 1 ... 9 10 11 12 13 14 15 16 17 ... 33 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |